Jennifer Wims-Madden
Psychiatric/Mental Health · Pontiac, MINPI 1245585710
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 61.5% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $14,385, 7.7 times the $1,879 reported in 2021. Among psychiatric/mental health clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 343 payments — averaging $80.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$17K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$1K
- Lundbeck LLC$1K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $4K from 13 others
What the payments were for
- Consulting fees$3951%
- Speaking & faculty fees$11,92643%
- Travel & lodging$1,9447%
- Food & beverage$13,20948%
- Education$1741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 61 | $16,994 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $1,837 |
| AbbVie | 63 | $1,443 |
| Lundbeck LLC | 54 | $1,255 |
| Johnson & Johnson | 24 | $1,200 |
| Otsuka America Pharmaceutical, Inc. | 23 | $1,097 |
| Axsome Therapeutics, Inc. | 10 | $683 |
| Alkermes, Inc. | 9 | $653 |
| E.r. Squibb & Sons, L.L.C. | 12 | $536 |
| Vanda Pharmaceuticals Inc. | 8 | $519 |
| Neurocrine Biosciences, Inc. | 8 | $462 |
| Janssen Scientific Affairs, LLC | 2 | $276 |
| Sunovion Pharmaceuticals Inc. | 16 | $244 |
| Indivior Inc. | 7 | $142 |
| Supernus Pharmaceuticals, Inc. | 2 | $134 |
| Bioxcel Therapeutics, Inc. | 2 | $110 |
| Vertical Pharmaceuticals, LLC | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $23 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$15,411
- LYBALVI$1,884
- CAPLYTA$1,339
- REXULTI$1,068
- INVEGA SUSTENNA$765
- Auvelity$585
- ARISTADA$500
- Fanapt$485
- VRAYLAR$471
- INGREZZA$353
- SPRAVATO$264
- AUSTEDO$252
- UZEDY$245
- INVEGA TRINZA$127
- ARISTADA INITIO$125
- COBENFY$125
- QELBREE$123
How this compares
$27,648 in reported general payments places this provider in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 50 | $70,379 |
| RexultiBrexpiprazole | 26 | $47,908 |
| CaplytaLumateperone Tosylate | 26 | $42,681 |
| Abilify MaintenaAripiprazole | 11 | $32,358 |
| Invega SustennaPaliperidone Palmitate | 13 | $31,495 |
| TrintellixVortioxetine Hydrobromide | 42 | $29,132 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $19,375 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 62 | $3,975 |
| Quetiapine Fumarate | 70 | $3,840 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 19 | $3,638 |
| Aripiprazole | 67 | $2,987 |
| Bupropion XlBupropion Hcl | 41 | $2,943 |
| Paliperidone ErPaliperidone | 21 | $2,072 |
| Buspirone Hcl | 91 | $1,780 |
| Trazodone Hcl | 121 | $1,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,097 | $80,26637 claims |
| AbbVieVraylar | $1,443 | $70,37950 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,837 | $42,68126 claims |
| Johnson & JohnsonInvega Sustenna | $1,200 | $31,49513 claims |
| Axsome Therapeutics, Inc.Auvelity | $683 | $19,37511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Other psychiatric/mental health in Pontiac
- Deborah HammondPontiac$6K
- Duren GutierrezSouthfield$207K
- Tamlynn EvansTraverse City$78K
- Shiba NixonClarkston$60K
- Amy AmesClinton Township$43K
- Cody ShinavierClarkston$41K
- Oksana LidkeBattle Creek$30K
- Jessica ShantzWarren$21K
- Gladys KimeliSaginaw$17K
- Cynthia MaiSaginaw$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.